All News
Anti-Drug Antibodies and Biologic Drug Responses
A prospective cohort study suggests the presence of antidrug antibodies may be associated with bDMARDs nonresponse in rheumatoid arthritis (RA). Should we be monitoring ADAbs (especially in nonresponders)?
Read Article
Methotrexate Nodulosis (1.19.2024)
Dr. Jack Cush reviews the news and journal reports from this past week on RheumNow.com. How good (or not) are rheumatologists and what to do about MTX nodulosis?
Read Article
Rituximab Efficacy in MAINRITSAN Long-Term Studies
The original randomized controlled, prospective MAINRITSAN study of 115 patients (87 with granulomatosis with polyangiitis, 23 with microscopic polyangiitis, and 5 with renal-limited ANCA-associated vasculitis [AAV]) demonstrated superiority of rituximab (RTX) over azathioprine (AZA) for maintenance of remission at 22 months in ANCA-associated vasculitis patients after CYC remission induction.
Read Article
2023 EULAR Non-pharmacological Management of Hip and Knee Osteoarthritis: 2023 update
EULAR has published the 2023 updated recommendations for the optimal non-pharmacological management of hip and knee osteoarthritis (OA).
Read Article
Allosteric versus active site inhibition by JAK.
Never understood this better.
Thanks to Bruce Strober.
#RNL2024
@RheumNow https://t.co/r9hhHLO5oS
Links:
Nouf Al hemmadi NoufAhmedAlham2 ( View Tweet)
JAK toxicity of interest.
Eric Ruderman
#RNL2024
@RheumNow https://t.co/qdlJFKTUR8
Nouf Al hemmadi NoufAhmedAlham2 ( View Tweet)
Do you check CPK on patients who are on JAK inhibitors? #RNL2024 @rheumnow
TheDaoIndex KDAO2011 ( View Tweet)
Clinical pearl!
Dr. Winthrop holds JAKi for one week after vaccination.
#RNL2024 @RheumNow https://t.co/BLiKu8xX7t
Dr. Rachel Tate uptoTate ( View Tweet)
Dr. Strober's JAKi in dermatology takeaways!
- Consider this for AD
- Dose matters in terms of both efficacy and toxicity
- Consider combination tx
- Topical JAKi option for vitiligo, especially head and neck involvement (harder in hands and other areas)
#RNL2024 @RheumNow https://t.co/ZrPfpUF4Hz
Dr. Rachel Tate uptoTate ( View Tweet)
JAKi toxicities of interest:
- Zoster
- Safety: VTE, MACE, Malignancies
- Lab abnormalities including CK, LFT, creatinine, and lipid elevations and cytopenias.
@JointMD #RNL2024
@rheumnow https://t.co/u72yz8uLYB
Dr. Rachel Tate uptoTate ( View Tweet)
đâEighty percent of drugs withdrawn from the market pose greater risk for women.â â Dr. Eder #RNL2024 @rheumnow #genderDifferences https://t.co/RZrIdvecbY
TheDaoIndex KDAO2011 ( View Tweet)
Welcome to the "FDA-approved" team Bimekizumab. Dr. Armstrong shows MOA of IL17a and IL17f dual inhibition, and the important PASI scores showing 2/3 of pts clear by week 16. @RheumNow #RNL2024 @_AprilArmstrong https://t.co/KiTcVsGzpD
Links:
Dr. Rachel Tate uptoTate ( View Tweet)
Meta-analysis of 35 RCTs (>20K pts) with inflammatory skin disorders shows that w/ short-term (<5 mos) use JAK inhibitors do not significantly increase risk of all-cause mortality (OR, 0.83; 0.44-1.57), MACE, or VTE (OR, 0.52; 0.26-1.04). https://t.co/zBlcZ02QqQ https://t.co/cXjswVS9lF
Dr. John Cush RheumNow ( View Tweet)
Rituximab Efficacy in MAINRITSAN Long-Term Studies
https://t.co/z16uMDihV4 https://t.co/BaWFcwDbYL
Dr. John Cush RheumNow ( View Tweet)
You can still attend RheumNow Live!
Below is a preview of one of our "STEP" talks - by Mike Putman, MD, who brings his vast knowledge to the forefront, shedding light on Myths & Mistakes on ANCA-Associated Vasculitis.
https://t.co/LzcVytLDij
Register: https://t.co/NWXKNhQzc5 https://t.co/ogAfTtH5Nk
Dr. John Cush RheumNow ( View Tweet)
Japanese retrospective study compared RA pts on JAK inhib vs bDMARDs (n=62 ea) having orthopedic surgery; JAKi- pts had more postoperative flares (29% v 12%, P=.01), esp if JAKi held >11d (p.04). No diff in other postop complications https://t.co/NVY1Oajdve https://t.co/fwc9KWYZ9l
Links:
Dr. John Cush RheumNow ( View Tweet)
Hepatitis B Virus Reactivation is possible w/ immunosuppression- most (>10%) w/ w/ Rituximab & stem cell transplants. If HBsAg positive, pts should recv anti-viral prophylaxis; HBsAgâ individuals should be evaluated on a case-by-case basis https://t.co/7JKorgWbYr https://t.co/RdW65u5KDR
Dr. John Cush RheumNow ( View Tweet)
QD Clinic - Suspend MTX How Long?
Pregnancy and MTX - how long do you have to be off?
https://t.co/pTz8nlHpWN https://t.co/YrG7cKgbvF
Dr. John Cush RheumNow ( View Tweet)
Prior RCT showed continuous NSAID slowed XRay progress in SpA. New 2 yr RCT of 109 pts shows when celecoxib added to TNFi Rx (golimumab) in high risk SpA there was no added Xray benefits (by mSASSS). https://t.co/i0KTPAaLFz https://t.co/dB2Q3PHhcK
Dr. John Cush RheumNow ( View Tweet)
Retrospective study of 170 #RA on TNFi (Inflx 53%, ADA 28%, CZP 19%). RF, CCP, Drug levels, anti-Drug Abs done.@6 mos HI baseline RF linked to lower drug levels for IFX & ADA; but not CZP. IFX/ADA Hi-RF pts had more dropouts vs CZP (80%/75%/33%, p=0.002) https://t.co/AIgJNkzcWu https://t.co/pQmfmLoFwe
Dr. John Cush RheumNow ( View Tweet)
